Kodiak Sciences Inc. (FRA:K27)

Germany flag Germany · Delayed Price · Currency is EUR
21.12
-0.92 (-4.17%)
Last updated: Dec 10, 2025, 8:02 AM CET
151.28%
Market Cap1.17B
Revenue (ttm)n/a
Net Income (ttm)-185.24M
Shares Outn/a
EPS (ttm)-3.51
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume16
Open21.12
Previous Close22.04
Day's Range21.12 - 21.12
52-Week Range1.72 - 22.04
Betan/a
RSI61.86
Earnings DateMar 26, 2026

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 109
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol K27
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.